HALO Quote, Financials, Valuation and Earnings

Catalyst Pharmaceuticals has a net margin of 45.98% compared to Halozyme Therapeutics's net margin of 39.44%. Halozyme Therapeutics's return on equity of 162.37% beat Catalyst Pharmaceuticals's return on equity of 27.81%.

Halozyme Therapeutics has a consensus price target of $67.75, signalling upside risk potential of 6.18%. On the other hand Catalyst Pharmaceuticals has an analysts' consensus of $33.88 which suggests that it could grow by 39.69%. Given that Catalyst Pharmaceuticals has higher upside potential than Halozyme Therapeutics, analysts believe Catalyst Pharmaceuticals is more attractive than Halozyme Therapeutics.

Halozyme Therapeutics has a beta of 1.323, which suggesting that the stock is 32.284% more volatile than S&P 500. In comparison Catalyst Pharmaceuticals has a beta of 0.786, suggesting its less volatile than the S&P 500 by 21.371%.

Halozyme Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Halozyme Therapeutics pays -- of its earnings as a dividend. Catalyst Pharmaceuticals pays out -- of its earnings as a dividend.

Halozyme Therapeutics quarterly revenues are $298M, which are larger than Catalyst Pharmaceuticals quarterly revenues of $141.8M. Halozyme Therapeutics's net income of $137M is higher than Catalyst Pharmaceuticals's net income of $55.9M. Notably, Halozyme Therapeutics's price-to-earnings ratio is 18.60x while Catalyst Pharmaceuticals's PE ratio is 18.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics is 8.13x versus 6.16x for Catalyst Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 45.98% compared to Halozyme Therapeutics's net margin of 15.24%. Halozyme Therapeutics's return on equity of 162.37% beat Johnson & Johnson's return on equity of 19.98%.

Halozyme Therapeutics has a consensus price target of $67.75, signalling upside risk potential of 6.18%. On the other hand Johnson & Johnson has an analysts' consensus of $169.07 which suggests that it could grow by 1.95%. Given that Halozyme Therapeutics has higher upside potential than Johnson & Johnson, analysts believe Halozyme Therapeutics is more attractive than Johnson & Johnson.

Halozyme Therapeutics has a beta of 1.323, which suggesting that the stock is 32.284% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.490, suggesting its less volatile than the S&P 500 by 50.995%.

Halozyme Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.99% to investors and pays a quarterly dividend of $1.24 per share. Halozyme Therapeutics pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Halozyme Therapeutics quarterly revenues are $298M, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. Halozyme Therapeutics's net income of $137M is lower than Johnson & Johnson's net income of $3.4B. Notably, Halozyme Therapeutics's price-to-earnings ratio is 18.60x while Johnson & Johnson's PE ratio is 28.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics is 8.13x versus 4.53x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of 45.98% compared to Halozyme Therapeutics's net margin of 23.96%. Halozyme Therapeutics's return on equity of 162.37% beat Merck &'s return on equity of 40.25%.

Halozyme Therapeutics has a consensus price target of $67.75, signalling upside risk potential of 6.18%. On the other hand Merck & has an analysts' consensus of $112.07 which suggests that it could grow by 24.85%. Given that Merck & has higher upside potential than Halozyme Therapeutics, analysts believe Merck & is more attractive than Halozyme Therapeutics.

Halozyme Therapeutics has a beta of 1.323, which suggesting that the stock is 32.284% more volatile than S&P 500. In comparison Merck & has a beta of 0.401, suggesting its less volatile than the S&P 500 by 59.879%.

Halozyme Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.52% to investors and pays a quarterly dividend of $0.81 per share. Halozyme Therapeutics pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Halozyme Therapeutics quarterly revenues are $298M, which are smaller than Merck & quarterly revenues of $15.6B. Halozyme Therapeutics's net income of $137M is lower than Merck &'s net income of $3.7B. Notably, Halozyme Therapeutics's price-to-earnings ratio is 18.60x while Merck &'s PE ratio is 13.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics is 8.13x versus 3.55x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Semler Scientific has a net margin of 45.98% compared to Halozyme Therapeutics's net margin of 41.51%. Halozyme Therapeutics's return on equity of 162.37% beat Semler Scientific's return on equity of 37.58%.

Halozyme Therapeutics has a consensus price target of $67.75, signalling upside risk potential of 6.18%. On the other hand Semler Scientific has an analysts' consensus of $71.00 which suggests that it could grow by 96.13%. Given that Semler Scientific has higher upside potential than Halozyme Therapeutics, analysts believe Semler Scientific is more attractive than Halozyme Therapeutics.

Halozyme Therapeutics has a beta of 1.323, which suggesting that the stock is 32.284% more volatile than S&P 500. In comparison Semler Scientific has a beta of 1.290, suggesting its more volatile than the S&P 500 by 29.027%.

Halozyme Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Semler Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Halozyme Therapeutics pays -- of its earnings as a dividend. Semler Scientific pays out -- of its earnings as a dividend.

Halozyme Therapeutics quarterly revenues are $298M, which are larger than Semler Scientific quarterly revenues of $12.4M. Halozyme Therapeutics's net income of $137M is higher than Semler Scientific's net income of $29.2M. Notably, Halozyme Therapeutics's price-to-earnings ratio is 18.60x while Semler Scientific's PE ratio is 7.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics is 8.13x versus 5.13x for Semler Scientific. Usually stocks with elevated PS ratios are considered overvalued.